Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Current Leases (2019 - 2025)

Historic Current Leases for Beam Therapeutics (BEAM) over the last 7 years, with Q3 2025 value amounting to $12.7 million.

  • Beam Therapeutics' Current Leases fell 191.71% to $12.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.7 million, marking a year-over-year decrease of 191.71%. This contributed to the annual value of $13.5 million for FY2024, which is 540.77% up from last year.
  • According to the latest figures from Q3 2025, Beam Therapeutics' Current Leases is $12.7 million, which was down 191.71% from $12.9 million recorded in Q2 2025.
  • Beam Therapeutics' Current Leases' 5-year high stood at $13.5 million during Q4 2024, with a 5-year trough of $3.5 million in Q2 2021.
  • In the last 5 years, Beam Therapeutics' Current Leases had a median value of $11.5 million in 2023 and averaged $10.4 million.
  • In the last 5 years, Beam Therapeutics' Current Leases tumbled by 2569.18% in 2021 and then skyrocketed by 17247.21% in 2022.
  • Quarter analysis of 5 years shows Beam Therapeutics' Current Leases stood at $7.5 million in 2021, then skyrocketed by 37.67% to $10.4 million in 2022, then increased by 23.1% to $12.8 million in 2023, then increased by 5.41% to $13.5 million in 2024, then dropped by 5.8% to $12.7 million in 2025.
  • Its Current Leases was $12.7 million in Q3 2025, compared to $12.9 million in Q2 2025 and $13.2 million in Q1 2025.